Olmetec Plus (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxomil is an angiotensin II receptor blocker that selectively inhibits the AT‑1 receptor, preventing angiotensin‑II‑induced vasoconstriction and aldosterone release, which helps relax blood vessels and lower blood pressure.

The prescribed dose of Olmetec Plus is determined by the treating physician based on the patient’s blood‑pressure readings, renal function and overall clinical profile. Dosage adjustments are made according to individual response and tolerability.

Olmetec Plus is contraindicated in pregnancy because olmesartan can cause fetal toxicity. It should be used only if the potential benefit justifies the risk. Limited data are available for breastfeeding; the drug may pass into milk, so a healthcare professional should evaluate the risk‑benefit ratio.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmetec Plus combines an ARB with a thiazide diuretic, offering dual mechanisms that can be more effective than monotherapy for patients needing both vasodilation and volume reduction. Compared with ACE‑inhibitor + diuretic combos, it has a lower incidence of cough but a similar risk profile for hyperkalemia and renal effects.

Store tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and do not use after the expiry date printed on the packaging.

Olmetec Plus is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, angio‑edema and liver function abnormalities. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, or marked changes in urine output.

Olmetec Plus should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide or any component of the formulation, in pregnant women, and in individuals with severe renal impairment or electrolyte disturbances unless closely monitored.